Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...380381382383384385386387388389390...10671068»
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia, Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech
    ADVERSE EVENTS FOLLOWING IMMUNISATION (AEFI) OF COVID-19 VACCINES IN KIDNEY PATIENTS- A CASE SERIES (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1484;    
    Patients with kidney diseases may experience different adverse events post vaccination unique to their underlying kidney diseases. Further studies are needed for better understanding of the effects of vaccination in the CKD population.
  • ||||||||||  piperacillin sodium/tazobactam sodium / Generic mfg., dexamethasone injection / Generic mfg., cefotaxime / Generic mfg.
    SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS SYNDROME REVEALING PLASMA-CELL LEUKEMIA IN A COVID-19 PATIENT PRESENTING WITH KIDNEY INJURY (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1471;    
    Further studies are needed for better understanding of the effects of vaccination in the CKD population. To conclude,It is difficult to distinguish if sHLH is due to SARS-CoV-2 itself,to co-infections by other microorganisms,or other etiologies.Thus, bone marrow examination and blood smear should be performed in COVID-19 patients presenting with cytopenia whenever possible.Due to the aggressive behavior of PCL,treatment should start as soon as possible.Severe kidney injury at presentation may be predictive of worse renal outcome.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford
    COVID ASSOCIATED MUCORMYCOSIS IN KIDNEY TRANSPLANT RECIPIENTS- A CASE SERIES (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1380;    
    They all had multiple risk factors that included elements of hyperglycemia, sepsis and nephrotoxic drugs (amphotericin B). Four of our five patients recovered, with only one case succumbing to the infection
  • ||||||||||  prednisone / Generic mfg., mycophenolate mofetil / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Cutaneous leishmaniasis in a kidney transplant patient: a case report (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1375;    
    It remains rare after kidney transplantation. However, it should always be kept in mind in this population in front of their acquired immunosuppression status.
  • ||||||||||  dexamethasone / Generic mfg.
    UNEXPECTED DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE IN DIABETIC WOMEN (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1115;    
    Morbidity associated with monoclonal gammopathy of renal significance is high due to the severe renal lesions and the associated systemic alterations. Accordingly, early diagnosis is fundamental, as is stopping the clonal production of immunoglobulins using specific chemotherapy.
  • ||||||||||  prednisolone / Generic mfg.
    AUTOIMMUNE PANCREATITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: CASE REPORT (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1110;    
    In many cases, this complication has been attributed to the drugs administered. In our case, a favorable course of pancreatitis with corticosteroids adds further evidence to the idea that lupus-related pancreatitis is not a side effect of corticosteroid therapy.
  • ||||||||||  dexamethasone / Generic mfg.
    THYROID DISEASE IN TIME OF COVID19 (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1081;    
    The predominant degree of pulmonary involvement was between 25 and 50% of the parenchyma in the majority of patients with hypothyroidism.Dexamethasone was used in all patients with respiratory impairment... More studies must be carried out to understand the possible complications of Covid 19 on thyroid function.
  • ||||||||||  chloroquine phosphate / Generic mfg., cyclophosphamide / Generic mfg., hydrocortisone / Generic mfg.
    POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME: AN UNDERRECOGNIZED MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1059;    
    While rare, patients with multiple risk factors for PRES should be monitored closely for disease management and prevention. Here we present a rare case of PRES in a 34-year-old female with previously undiagnosed lupus nephritis and favorable outcome after plasmapheresis.
  • ||||||||||  dexamethasone / Generic mfg.
    C1Q NEPHROPATHY CAUSING ADVANCED CKD IN THE COVID 19 ERA : A PATIENT WHO RECOVERED TO BASELINE RENAL FUNCTION POST SARS-COV2 AKI ON CKD (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1040;    
    C1q nephropathy has been thought to be a subgroup of primary focal segmental glomerulosclerosis as 0.02% cases with FSGS can be associated with C1q nephropathy but most recent reports suggest that C1q nephropathy may be a combination of several disease groups rather than a single disease entity. C1q usually progresses to ESKD and progression to renal replacement therpay may be unpreventable despite all efforts of treatment.
  • ||||||||||  prednisolone / Generic mfg.
    INDOLENT INTERSTITIAL NEPHRITIS IN A PATIENT WITH IgG4 RELATED KIDNEY DISEASE (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_737;    
    A diagnosis of IgG4 related interstitial nephritis was made and oral prednisolone 30 mg daily was started. A high degree of clinical suspicion and histopathological examination is crucial to aid in the diagnosis.
  • ||||||||||  cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    SERONEGATIVE ANTI GBM GLOMERULONPEHRITIS (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_704;    
    1. The enzyme-linked immunosorbent assay (ELISA) is an imperfect laboratory test and may represent a false-negative result.
  • ||||||||||  cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    LONG TERM RENAL AND PATIENT SURVIVAL IN LUPUS NEPHRITIS PATIENT TREATED IN UKKMC MALAYSIA. (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_697;    
    Majority of patients (96.7%) were induced with IV pulsed methylprednisolone and IV Cyclophosphamide (Cyclo) with cumulative dose of 4.14 ± 2.27gram over 5.48 ± 2.03 months. Our treatment protocol resulted in comparable long term renal and patients’ survival to most LN studies reported worldwide.
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia
    NEW ONSET NEPHROTIC SYNDROME FOLLOWING INACTIVATED SARS-CoV-2 VACCINE (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_694;    
    Triggers such as medication e.g. NSAIDs, bee sting, malignancy and vaccines are known to be associated with MCD. The exact mechanism of triggering MCD post vaccine was not well established.
  • ||||||||||  prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IgG DEPOSITS; A NOVEL PATHOLOGIC PRESENTATION. (Poster Area (Virtual)) -  Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_686;    
    Our case is a unique presentation of PGNMID in a patient who presented with clinical and pathologic features concerning for Goodpasture syndrome. PGNMID can rarely present with diffuse crescents and IF findings similar to anti-GBM nephritis in a patient with RPGN.
  • ||||||||||  inobrodib (CCS1477) / CellCentric
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  CCS1477-02: Study to Evaluate CCS1477 in Haematological Malignancies (clinicaltrials.gov) -  Jan 21, 2022   
    P1/2,  N=90, Recruiting, 
    Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023 Trial completion date: Dec 2021 --> Mar 2024 | Trial primary completion date: Dec 2021 --> Mar 2024
  • ||||||||||  carboplatin / Generic mfg., olanzapine / Generic mfg.
    Trial completion:  OLN-EME: Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis (clinicaltrials.gov) -  Jan 21, 2022   
    P3,  N=90, Completed, 
    Trial completion date: Dec 2021 --> Mar 2024 | Trial primary completion date: Dec 2021 --> Mar 2024 Recruiting --> Completed
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Current Overviews on COVID-19 Management Strategies. (Pubmed Central) -  Jan 20, 2022   
    Plant-based anti-viral compounds such as baicalin, calanolides, curcumin, oxymatrine, matrine, and resveratrol exhibit different modes of action against a wide range of positive/negative sense-RNA/DNA virus, and future researches need to be conducted to ascertain their role, use in managing SARS-CoV-2. Thus, this article is an attempt to review the current understanding of COVID-19 acute respiratory disease and summarize its clinical features with their prospective control and various aspects of the therapeutic approach.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Retrospective data, Journal:  Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. (Pubmed Central) -  Jan 20, 2022   
    Lenalidomide is an important component of initial therapy in newly diagnosed multiple myeloma, either as maintenance therapy post-autologous stem cell transplantation (ASCT) or as first-line therapy with dexamethasone for patients' ineligible for ASCT (non-ASCT)...Among 256 patients who progressed on lenalidomide maintenance therapy, 28.5% received further immunomodulatory derivative-based (IMiD-based) therapy (lenalidomide/pomalidomide) without a proteasome inhibitor (PI) (bortezomib/carfilzomib/ixazomib), 26.2% received PI-based therapy without an IMiD, 19.5% received both an IMiD plus PI, 13.5% received daratumumab-based regimens, and 12.1% underwent salvage ASCT...During most of the study period, daratumumab was not funded; in this setting, switching to a different therapeutic class following relapse on lenalidomide produced the longest remissions for non-ASCT patients. Further prospective studies are warranted to determine optimum treatment following relapse on lenalidomide, especially in the light of increased access to daratumumab.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Salidroside protects against ventilation-induced lung injury by inhibiting the expression of matrix metalloproteinase-9. (Pubmed Central) -  Jan 20, 2022   
    In vitro, mouse lung vascular endothelial cells (MLVECs) were treated with salidroside, MMP-9 siRNA, and BAY11-7082 (10 μM), and then exposed to cyclic stretch for 4 h...Salidroside protected against stretch-induced endothelial barrier function, improving lung injury after ventilation. Thus, salidroside may be a promising therapeutic agent for patients with MV-induced lung injury.
  • ||||||||||  Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Trial completion date:  Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) -  Jan 20, 2022   
    P1/2,  N=28, Active, not recruiting, 
    Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Oct 2022 Trial completion date: Dec 2021 --> Apr 2022
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  NCI-2018-01129: Dexamethasone in Controlling Dyspnea in Patients With Cancer (clinicaltrials.gov) -  Jan 20, 2022   
    P2,  N=135, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2021 N=201 --> 135 | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 | Recruiting --> Active, not recruiting
  • ||||||||||  dexamethasone injection / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  POTEISS: Prediction of TEI Success in Sciatica (clinicaltrials.gov) -  Jan 20, 2022   
    P=N/A,  N=388, Recruiting, 
    N=201 --> 135 | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Oct 2021 --> Oct 2022 | Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Dec 2023